News and analysis on disease research and diagnostics.
For the three months ended Dec. 31, 2020, the firm reported $400,000 in pharmaceutical service revenue compared to none in 2019.
The company is working to expand access to its liquid biopsy assay outside of the US, after receiving US Food and Drug Administration approval last year.
The test uses a technology called Switch-Blocker that is co-owned by the companies and enables both viral detection and strain discrimination.
The new service, slated for launch in the second half of 2021, will allow Myriad to expand its cancer tumor profiling services.
The test uses prognostic markers to group women based on their risk of 10-year recurrence of ductal carcinoma in situ.
